INKT – mink therapeutics, inc. (US:NASDAQ)
Stock Stats
News
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting [Yahoo! Finance]
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
FairJourney Biologics Appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering [Yahoo! Finance]
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at Robert W. Baird from $8.00 to $4.00. They now have an "outperform" rating on the stock.
Form DEF 14A MiNK Therapeutics, Inc. For: Jan 17
Form 4 MiNK Therapeutics, Inc. For: Oct 30 Filed by: Kadlec Robert Peter
Form 3 MiNK Therapeutics, Inc. For: Oct 30 Filed by: Kadlec Robert Peter
Form PRE 14A MiNK Therapeutics, Inc. For: Jan 17
Form 4 MiNK Therapeutics, Inc. For: Dec 01 Filed by: Ryan Barbara
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.